Key Highlights
- The third-quarter net loss widened to USD 25.1 million from USD 14.2 million, or USD 0.54 per share versus USD 0.52, as the weighted share count rose to 46.5 million from 27.1 million.
- Research and development expense rose to USD 18.2 million from USD 10.5 million, with direct ALTO-207 spending of USD 7.2 million against USD 0.3 million a year earlier.
- Cash, cash equivalents and restricted cash were USD 319.8 million on September 30, 2026, up from USD 177.0 million at year-end, after a July offering with net proceeds of USD 94.6 million.
- The nine-month net loss was USD 79.0 million compared with USD 47.1 million, and general and administrative expense for the third quarter was USD 9.1 million versus USD 4.4 million.
Larger Quarterly Loss Driven by the ALTO-207 Phase 2b Trial
Alto Neuroscience (NYSE:ANRO) filed its Quarterly Report on November 10, 2026, showing a third-quarter net loss of USD 25.1 million against USD 14.2 million. The company has no product revenue, so the loss tracks operating spending, which rose to USD 27.2 million from USD 15.0 million. Research and Development was USD 18.2 million, and the filing attributes about USD 6.9 million of the increase to ALTO-207, which began a Phase 2b trial in April 2026 and has Manufacturing costs running alongside. Personnel costs added USD 1.6 million, partly offset by a USD 1.0 million drop in ALTO-101 spending after its proof-of-concept study. General and administrative expense reached USD 9.1 million on staffing and professional fees. Interest income of USD 2.6 million partly offset costs.
USD 319.8 Million Cash Position After the July Share Sale
The company is a clinical-stage drug developer focused on psychiatric conditions, including treatment-resistant depression, and it reported cash, cash equivalents and restricted cash of USD 319.8 million. A registered offering of 3,776,436 shares at USD 26.48, closed on July 14, 2026, brought in about USD 94.6 million after costs. The filing says existing cash plus anticipated proceeds under a convertible grant agreement with Wellcome should fund operations for at least the next 12 months. It also warns the company will need substantial additional capital. Equity raises of this kind add shares, which is why the loss per share rose only to USD 0.54 even though the net loss grew about 77% (calculated from the two reported totals).
Trial Readouts Due in 2027 and the Setback in ALTO-101
The filing lists seven clinical-stage assets. ALTO-207 topline data from its Phase 2b are expected in the second half of 2027, with an adjunctive Phase 3 trial expected to start by early 2027 and a monotherapy Phase 3 in the second half of 2027. ALTO-300 topline data in major depressive disorder are expected in the first half of 2027, and ALTO-100 data in bipolar depression in mid-2027. In April 2026 the Phase 2 study of ALTO-101 in cognitive Impairment tied to schizophrenia missed its primary endpoints, though the company points to directional EEG signals and plans to explore partnering for a modified-release formulation. Alto Neuroscience (NYSE:ANRO) has no commercial products, so every readout carries trial risk.
Where Things Stand
On the company's own estimate, the cash covers at least the next 12 months, though it expects to need more capital. Alto Neuroscience (NYSE:ANRO) widened its quarterly loss as the ALTO-207 Phase 2b ramped, yet it ended September with USD 319.8 million of cash, which the filing says covers at least the next 12 months. Dilution remains a risk. Key markers are the adjunctive Phase 3 start by early 2027, ALTO-300 topline data in the first half of 2027 and ALTO-100 data in mid-2027.






Please wait processing your request...